Search results
Bull of the Day: CRISPR Therapeutics (CRSP)
Zacks via Yahoo Finance· 6 months agoCRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that...
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
Motley Fool via Yahoo Finance· 4 months agoCRISPR Therapeutics (NASDAQ: CRSP) was a standout in the market last month as its shares charged 34%...
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
TipRanks via Yahoo Finance· 2 months agoCRISPR Therapeutics (NASDAQ:CRSP) stock has been slowly heading lower in recent months, and I don’t...
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
Motley Fool via Yahoo Finance· 6 months agoCRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The...
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 7 months agoA month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have...
CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected
Zacks via Yahoo Finance· 8 months agoCRISPR Therapeutics CRSP reported a net loss per share of $1.41 in the third quarter of 2023,...
CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 5.1% decline adds to one-year losses, institutional...
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Given the large stake in the stock by institutions, CRISPR Therapeutics' stock price...
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 months agoOn CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on...
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
Motley Fool via Yahoo Finance· 6 months ago"The thrill of victory and the agony of defeat." That phrase became well-known years ago thanks to...
Crispr Therapeutics Stock: Bull vs. Bear
Motley Fool· 2 years agoCrispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology. The biotech company is submitting its candidate to...
